Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
Ascendis Pharma A stock last closed at $219.73, down 2.2% from the previous day, and has increased 79.74% in one year. It has overperformed other stocks in the Biotechnology industry by 1.1 percentage points. Ascendis Pharma A stock is currently +86.16% from its 52-week low of $118.03, and -9.2% from its 52-week high of $242.00.
There are currently 61.1M ASND shares outstanding. The market cap of ASND is $13.43B. In the past 24 hours, 767,000 ASND shares were traded.
How to Buy Ascendis Pharma A Stock
Not sure how to invest in Ascendis Pharma A stock? Here's how.
Figure out where to buy Ascendis Pharma A stock: You need to choose an online brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you figure out where to buy Ascendis Pharma A stock.
Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
Deposit money your brokerage account: Pick your payment method and add your info.
Research Ascendis Pharma A stock: The Ascendis Pharma A ticker symbol is ASND. Is Ascendis Pharma A stock a good investment? Should you buy shares of ASND? How do ASND's underlying business fundamentals look? Do top analysts think Ascendis Pharma A is a good buy? Why has ASND's stock price moved recently? (Hint: Our stock market research tools can help you figure out if ASND is a good stock to buy).
Make your ASND trade: Decide if you will purchase ASND shares at the current market price or use a limit order to buy ASND stock at a specific price.
Get updates on your investment in ASND: Create a watchlist to get the latest news on your position in Ascendis Pharma A shares.
Step 1: Figure out where to buy Ascendis Pharma A stock
You need an online brokerage account to access the NASDAQ market and buy ASND shares.
A brokerage account is an investment account that enables you to buy and sell a number of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
We believe that eToro is the best place to buy stocks. eToro gives you:
Invest in stocks with zero commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
Access to global financial markets: From Technology to Financial Services, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've picked the right brokerage, you'll need to fill out some personal information so you can buy ASND stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Ascendis Pharma A stock
After you have chosen the best place to buy Ascendis Pharma A stock, it's very important to evaluate their stock prior to investing, so you actually comprehend the risk and opportunity.
Ascendis Pharma A Metrics
ASND Price
$219.73
1w %
-1.22%
1y %
79.74%
5y %
45.63%
P/E
-48.96x
P/B
-66.33x
P/S
17.86x
PEG
N/A
Revenue
$751.80M
Earnings
-$270.86M
Fore. Rev. Growth
50.63%
Fore. Earn. Growth
N/A
Market Cap
$13.43B
Next Earnings
Feb 12, 2026
Next Dividend
N/A
Ascendis Pharma A Fundamentals
WallStreetZen was designed to help average investors perform better fundamental analysis in minutes instead of hours.
There are more short-term assets than short-term liabilities on the ASND balance sheet.
ASND has $626.85M in cash and short term investments. This is sufficient to cover its annual cash burn of $130.41M.
There are more short-term assets than long-term liabilities on the ASND balance sheet.
ASND has cash burn of 130411627. It has enough cash and short-term investments to cover this for at least one year.
Failed Financial Due Diligence Checks:
ASND profit margin has gone up by 0.94 percentage points in the past year, but the company is still unprofitable.
ASND debt to equity ratio of -7.63 is negative.
Total ASND debt is still negative.
Is ASND stock a Buy, Hold, or Sell, according to analysts?
Out of 11 Equities analysts who track ASND, the consensus analyst rating on ASND is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Latest ASND Analyst Forecasts
Alex Thompson, a top 14% analyst from Stifel Nicolaus maintains ASND with a strong buy rating and raises their ASND price target from $254.00 to $256.00, on Dec 11, 2025.
Stifel Nicolaus's Alex Thompson raised their price target on Ascendis Pharma A (NASDAQ: ASND) by 0.8% from $254 to $256 on 2025/12/11. The analyst maintained their Strong Buy rating on the stock.
In a 2026 preview note on names in their Biotechnology portfolio, Thompson explained that Stifel Nicolaus undertook "refreshed diligence" on many companies in the group, making a number of model, estimate, and price target adjustments.
Yun Zhong, a bottom 4% analyst from Wedbush reiterates ASND with a buy rating and maintains their ASND price target from $220.00 to $220.00, on Nov 18, 2025.
Martin Auster, a top 24% analyst from Raymond James initiates coverage on ASND with a strong buy rating and announces their ASND price target of $271.00, on Oct 17, 2025.
Li Watsek, a bottom 20% analyst from Cantor Fitzgerald maintains ASND with a strong buy rating and raises their ASND price target from $203.00 to $254.00, on Oct 13, 2025.
Jessica Fye, a top 4% analyst from JP Morgan maintains ASND with a strong buy rating and raises their ASND price target from $260.00 to $264.00, on Oct 9, 2025.
Last year, ASND revenue was $751.80M. Over the past five year, ASND's revenue has increased by 134.95% per year. This was faster than the Biotechnology industry average of 43.3%.
No, Ascendis Pharma A doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Make your ASND trade
There are two main options:
Market order: A market order is an order to buy or sell a security at the best price on the market. Market orders are generally sufficient.
Limit order: A limit order lets you buy or sell a security at a specific price (or better). If you want to ensure you're buying or selling at an exact dollar amount limit, place a limit order.
Press the Open button and your broker will execute the order.
If you want more info about investing in stocks on eToro, click the helpful video below:
How much does it cost to buy one Ascendis Pharma A share?
As of Feb 4, 2026, it costs $219.73 to buy one share of Ascendis Pharma A stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $100, you can buy 0.455 shares of ASND.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.